Yong Xin (4726-TW) In addition to deploying traditional biological drugs, in recent years, it has actively entered the field of emerging biological drugs, including allogeneic cell therapy, ADC (antibody drug complex) drugs, etc. Among them, ADC drugs have joined hands with Jianyi Biotech, and have received 100 million yuan in drug development projects, and began to contribute revenue in the second half of this year.
Yongxin’s main customers are concentrated in the Asian market, and most of them are Japan and South Korea. Chen Peijun, chairman and general manager, said that due to the recent poor economic conditions, customers have deferred payment, which also shows the importance of developing emerging biopharmaceutical fields.
Among them, in terms of ADC drugs, together with Shengde, they have acquired about 40% of the equity of Jianyi Biotechnology. The two parties have already won a drug development project worth 100 million yuan in Japan. The drug development time is 18 months. It is expected that there will be revenue contributions from the second half of the year to next year.
In the part of allogeneic cell therapy, Yongxin cooperated with StemCyte of Yongsheng Biotechnology, and Yongsheng Biotechnology provided stem cells. At present, it has contributed a small amount of revenue, and will become strategic partners with other industry players in the next year.
Yongxin’s cell therapy pilot factory located in the No. 2 Biotechnology Building of the Hsinchu Biomedical Park will be completed next year. The first phase is to build a 50-liter allogeneic cell therapy PIC/S GMP factory.
2023-07-24 09:49:34
#Yong #Xin #Shuo #deployment #ADC #emerging #biological #drugs #gained #revenue #year #Anue #JuhengTaiwan #stock #news
